WAY-200070 is primarily studied for its potential therapeutic applications in the field of medicine, particularly in the treatment of osteoporosis and other bone-related disorders. It functions as a selective estrogen receptor beta agonist, which helps in promoting bone formation and reducing bone resorption. This makes it a promising candidate for addressing conditions where bone density is compromised. Additionally, its role in estrogen receptor signaling suggests potential benefits in neuroprotection and cognitive health, though research in these areas is still in early stages. Its application could extend to treating postmenopausal symptoms and other estrogen-related conditions, offering a targeted approach with fewer side effects compared to traditional hormone therapies. Further clinical studies are essential to fully understand its efficacy and safety profile.